Camilleri, Michael
Ford, Alexander C.
Mawe, Gary M.
Dinning, Phil G.
Rao, Satish S.
Chey, William D.
Simrén, Magnus
Lembo, Anthony
Young-Fadok, Tonia M.
Chang, Lin
Article History
First Online: 14 December 2017
Competing interests
: M.C. serves on an advisory board for Ironwood Pharmaceuticals and Shire Pharmaceuticals, with compensation to his employer and not to him personally, and has received grant and research support from NGM Pharmaceuticals. A.C.F. has received grant and research support from Almirall and has acted as a consultant and speaker for Almirall, Norgine and Shire Pharmaceuticals. S.S.R. serves on the advisory board for Forest Labs, Salix Pharmaceuticals, Takeda Pharmaceuticals and Synergy Pharmaceuticals and has received research grants from Forest Labs and Medtronic Corporation. M.S. has received grant and research support from Danone Nutricia Research and Ferring Pharmaceuticals and has acted as a consultant and speaker for Allergan, Almirall, Danone Nutricia Research, Menarini, Nestlé, Shire Pharmaceuticals, Takeda Pharmaceuticals and Tillotts. L.C. has served on advisory boards for BioAmerica, Cairn Diagnostics, IM Healthcare Science LLC, Napo Pharmaceuticals, Salix Pharmaceuticals, and Synergy Pharmaceuticals. All other authors have no relevant conflicts of interest related to the content of this Primer to declare.